38.67
-1.06(-2.67%)
Currency In USD
| Previous Close | 39.73 |
| Open | 39.78 |
| Day High | 39.78 |
| Day Low | 38.6 |
| 52-Week High | 41.24 |
| 52-Week Low | 24.05 |
| Volume | 3.69M |
| Average Volume | 4.21M |
| Market Cap | 16.79B |
| PE | 22.1 |
| EPS | 1.75 |
| Moving Average 50 Days | 37.76 |
| Moving Average 200 Days | 35.23 |
| Change | -1.06 |
If you invested $1000 in Royalty Pharma plc (RPRX) since IPO date, it would be worth $958.36 as of December 09, 2025 at a share price of $38.67. Whereas If you bought $1000 worth of Royalty Pharma plc (RPRX) shares 3 years ago, it would be worth $979.73 as of December 09, 2025 at a share price of $38.67.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement
GlobeNewswire Inc.
Dec 04, 2025 12:10 PM GMT
NEW YORK and SOUTH SAN FRANCISCO, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Denali Therapeutics, Inc. (Nasdaq: DNLI) today announced a $275 million synthetic royalty funding agreement based on future net sales
Royalty Pharma Acquires Royalty Interest in Alnylam’s AMVUTTRA for $310 Million from Blackstone Life Sciences
GlobeNewswire Inc.
Nov 04, 2025 12:15 PM GMT
NEW YORK and CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a royalty interest in Alnylam’s AMVUTTRA from funds managed by Blackstone Life Sciences (“Blackstone”) for $310
Royalty Pharma Declares Fourth Quarter 2025 Dividend
GlobeNewswire Inc.
Oct 17, 2025 12:15 PM GMT
NEW YORK, Oct. 17, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2025 of $0.22 per Class A ordinary share. The dividend will be paid on December